Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03049618 · ClinicalTrials.gov registry record · Phase 2

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

A Phase 2 study of Head and Neck Squamous Cell Carcinoma and Stage IIIA Non-Small Cell Lung Cancer, sponsored by University of Southern California.

Compiled by PlainTrial · August 8, 2026

Completed
Registry status: Phase 2
Development phase: 42
Enrollment target: 1
Study location

NCT03049618: Completed Phase 2 study of Head and Neck Squamous Cell Carcinoma and Stage IIIA Non-Small Cell Lung Cancer, sponsored by University of Southern California.

NCT03049618 is a Phase 2 study of Head and Neck Squamous Cell Carcinoma and Stage IIIA Non-Small Cell Lung Cancer that has completed, run by University of Southern California. The registered enrollment target is 42 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03049618, a Phase 2 study of Head and Neck Squamous Cell Carcinoma and Stage IIIA Non-Small Cell Lung Cancer, has completed, sponsored by University of Southern California.

COMPLETED
Registry status: Phase 2
Development phase: 42 participants
Enrollment target: 1
Study location

Study Summary

This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. Recombinant EphB4-HSA fusion protein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Giving recombinant EphB4-HSA fusion protein and pembrolizumab may work better in treating patients with non-small cell lung or head and neck squamous cell cancer.

Primary Outcome

Calculated based on the evaluable population of patients who received at least 1 dose of therapy. Overall response rate (ORR) is complete response (CR) + partial response (PR) recorded from study entry until disease progression based on RECIST v1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response

Conditions Studied

Head and Neck Squamous Cell Carcinoma Stage IIIA Non-Small Cell Lung Cancer EGFR Gene Mutation Metastatic Head and Neck Carcinoma Recurrent Non-Small Cell Lung Carcinoma Recurrent Head and Neck Carcinoma BRAF Gene Mutation Stage III Non-small Cell Lung Cancer ALK Gene Mutation ROS1 Gene Mutation

Interventions

BIOLOGICAL Pembrolizumab
OTHER Laboratory Biomarker Analysis
BIOLOGICAL Recombinant EphB4-HSA Fusion Protein

Study Locations (1)

California

USC / Norris Comprehensive Cancer Center - Los Angeles

Trial Details

Field	Value
Enrollment Target	42 participants
Start Date	2017-03-10
Est. Completion	2024-09-04
Phase	Phase 2

University of Southern California

617 total trials

What the finished NCT03049618 record still lists

NCT03049618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (64% lower).

The record links to 10 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT03049618 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03049618 about?

NCT03049618 is a clinical study titled "Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475". This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. Recombina...

What is the current status of trial NCT03049618?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2017-03-10. Estimated completion is 2024-09-04.

What conditions does trial NCT03049618 study?

This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, EGFR Gene Mutation, Metastatic Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma.

What interventions are being tested in trial NCT03049618?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL).

Who is sponsoring clinical trial NCT03049618?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03049618 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03049618's enrollment target sits among peer trials

42 77th of 124 higher than 48 of 124 other Head and Neck Squamous Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03049618, the US trial registry maintained by the National Library of Medicine. NCT03049618 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.